tetano
Editor, Senior Moderator
IJU Case Rep
. 2020 Oct 5;10.1002/iju5.12226.
doi: 10.1002/iju5.12226. Online ahead of print.
Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone
Ryo Tanaka[SUP] 1 [/SUP], Yoichi Kakuta[SUP] 1 [/SUP], Koichi Tsutahara[SUP] 1 [/SUP], Masahiro Nakagawa[SUP] 1 [/SUP], Naotsugu Ichimaru[SUP] 2 [/SUP], Katsuhiko Sakaguchi[SUP] 2 [/SUP], Taigo Kato[SUP] 3 [/SUP], Ryoichi Imamura[SUP] 3 [/SUP], Norio Nonomura[SUP] 3 [/SUP], Tetsuya Takao[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: The data of immunosuppressive therapy management on solid organ transplant recipients with coronavirus disease 2019 are insufficient. We report a kidney transplant recipient who developed coronavirus disease 2019 pneumonia, with successful management of low-dose mPSL.
Case presentation: A 36-year-old man, who underwent living kidney transplantation 1.5 year prior, developed fever. After 10 days, he developed dyspnea, and his blood oxygen levels decreased. Computed tomography showed pulmonary ground-glass shadow on both lungs, and the coronavirus disease 2019 real-time polymerase chain reaction test was positive. After reducing the immunosuppressive agents, the C-reactive protein levels continued elevating, and the pulmonary shadow spread. Subsequently, low-dose methylprednisolone (40 mg/day) was administered for 4 days and his C-reactive protein and blood oxygen levels increased and improved, respectively. The coronavirus disease 2019 real-time polymerase chain reaction test was negative and the pulmonary shadow disappeared.
Conclusion: Low-dose methylprednisolone may prevent the development of severe coronavirus disease 2019.
Keywords: COVID‐19; immunosuppressive therapy; kidney transplantation; low‐dose methylprednisolone; solid organ transplant.
. 2020 Oct 5;10.1002/iju5.12226.
doi: 10.1002/iju5.12226. Online ahead of print.
Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone
Ryo Tanaka[SUP] 1 [/SUP], Yoichi Kakuta[SUP] 1 [/SUP], Koichi Tsutahara[SUP] 1 [/SUP], Masahiro Nakagawa[SUP] 1 [/SUP], Naotsugu Ichimaru[SUP] 2 [/SUP], Katsuhiko Sakaguchi[SUP] 2 [/SUP], Taigo Kato[SUP] 3 [/SUP], Ryoichi Imamura[SUP] 3 [/SUP], Norio Nonomura[SUP] 3 [/SUP], Tetsuya Takao[SUP] 1 [/SUP]
Affiliations
- PMID: 33230502
- PMCID: PMC7675346
- DOI: 10.1002/iju5.12226
Abstract
Introduction: The data of immunosuppressive therapy management on solid organ transplant recipients with coronavirus disease 2019 are insufficient. We report a kidney transplant recipient who developed coronavirus disease 2019 pneumonia, with successful management of low-dose mPSL.
Case presentation: A 36-year-old man, who underwent living kidney transplantation 1.5 year prior, developed fever. After 10 days, he developed dyspnea, and his blood oxygen levels decreased. Computed tomography showed pulmonary ground-glass shadow on both lungs, and the coronavirus disease 2019 real-time polymerase chain reaction test was positive. After reducing the immunosuppressive agents, the C-reactive protein levels continued elevating, and the pulmonary shadow spread. Subsequently, low-dose methylprednisolone (40 mg/day) was administered for 4 days and his C-reactive protein and blood oxygen levels increased and improved, respectively. The coronavirus disease 2019 real-time polymerase chain reaction test was negative and the pulmonary shadow disappeared.
Conclusion: Low-dose methylprednisolone may prevent the development of severe coronavirus disease 2019.
Keywords: COVID‐19; immunosuppressive therapy; kidney transplantation; low‐dose methylprednisolone; solid organ transplant.